Table 1.
Groups and Treatment Paradigms for Agonist, Antagonist, and Vehicle Injections in Guinea Pigs
| Group Number | Group Name | Treatment | Sample Size |
|---|---|---|---|
| 1 | N+Butaprost (1 µmol/L) | EP2 agonist injections in a normal visual environment | 17 |
| 2 | N+Butaprost (10 µmol/L) | EP2 agonist injections in a normal visual environment | 18 |
| 3 | N+AH6809 (10 µmol/L) | EP2 antagonist injections in a normal visual environment | 18 |
| 4 | N+AH6809 (30 µmol/L) | EP2 antagonist injections in a normal visual environment | 18 |
| 5 | N+DMSO | Vehicle injection in a normal visual environment | 18/19*(in butaprost/ AH6809 groups, respectively) |
| 6 | FD | Form deprivation | 19 |
| 7 | FD+Butaprost (1 µmol/L) | EP2 agonist injections with form deprivation | 15 |
| 8 | FD+Butaprost (10 µmol/L) | EP2 agonist injections with form deprivation | 12 |
| 9 | FD+AH6809 (10 µmol/L) | EP2 antagonist injections with form deprivation | 18 |
| 10 | FD+AH6809 (30 µmol/L) | EP2 antagonist injections with form deprivation | 17 |
| 11 | FD+DMSO | Vehicle injection with form deprivation | 15/18* (in Butaprost/ AH6809 groups, respectively) |
| 12 | AM | Untreated age-matched controls | 20 |
*Butaprost and AH6809 injection groups had separate sets “N+DMSO” and “FD+DMSO” controls for parallel comparison across drug and vehicle injection treatment paradigms.